{"id":"W4281396346","doi":"10.2217/fon-2021-1629","title":"Targeting <i>FGFR3</i> Alterations with Adjuvant Infigratinib in Invasive Urothelial Carcinoma: the Phase III PROOF 302 Trial","year":2022,"lang":"en","type":"article","venue":"Future Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Helsinn","keywords":"Medicine; Placebo; Clinical endpoint; Tolerability; Metastatic Urothelial Carcinoma; Internal medicine; Oncology; Adjuvant; Bladder cancer; Cisplatin; Urothelial cancer; Urology; Randomized controlled trial; Adverse effect; Urothelial carcinoma; Cancer; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001250087,0.001108517,0.001359478,0.0002157078,0.0002664489,0.0008878862,0.0006152311,0.001145081,0.005148259],"category_scores_gemma":[0.000808869,0.0002689563,0.001162821,0.0002509824,0.0005652738,0.0006473656,0.0003217073,0.002148418,0.0009516444],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007127312,"about_ca_system_score_gemma":0.001215272,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008050343,"about_ca_topic_score_gemma":0.002379786,"domain_scores_codex":[0.9997534,0.0001168567,0.00001485329,0.00003803345,0.00002983822,0.00004698135],"domain_scores_gemma":[0.9997218,0.00005053459,0.00007723401,0.00002500632,0.00002517801,0.0001002856],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7188585,0.01581025,0.002660011,0.004312626,0.00202077,0.0002184954,0.0002061103,0.002667284,0.05036065,0.001630566,0.02120432,0.1800504],"study_design_scores_gemma":[0.8130772,0.1642653,0.0048481,0.0001546631,0.0006553707,0.0003925523,0.00005564186,0.001240536,0.004232035,0.0007396633,0.01030004,0.00003896245],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9536688,0.01614148,0.002163412,0.003020156,0.0005917864,0.007502061,0.005347783,0.0006055759,0.01095899],"genre_scores_gemma":[0.9678726,0.006650869,0.004046912,0.002709638,0.0002509695,0.005135508,0.006209004,0.0000862872,0.007038099],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005148259,"threshold_uncertainty_score":0.01722264,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01913689018658343,"score_gpt":0.3077494896688529,"score_spread":0.2886125994822695,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}